Cetera Investment Advisers Has $1.41 Million Holdings in Autolus Therapeutics PLC Sponsored ADR $AUTL

Cetera Investment Advisers lifted its position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 17.6% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 617,172 shares of the company’s stock after acquiring an additional 92,300 shares during the period. Cetera Investment Advisers’ holdings in Autolus Therapeutics were worth $1,407,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Autolus Therapeutics in the second quarter valued at $50,000. Invesco Ltd. increased its stake in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Delaney Dennis R bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $55,000. Forefront Wealth Management Inc. acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at about $61,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in Autolus Therapeutics by 63.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock worth $69,000 after purchasing an additional 11,821 shares during the period. 72.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AUTL. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, November 3rd. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company decreased their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Finally, Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.33.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $1.38 on Tuesday. The firm has a market cap of $367.27 million, a price-to-earnings ratio of -1.66 and a beta of 2.01. The stock’s fifty day moving average price is $1.49 and its two-hundred day moving average price is $1.81. Autolus Therapeutics PLC Sponsored ADR has a one year low of $1.11 and a one year high of $3.45.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The business had revenue of $21.19 million during the quarter, compared to the consensus estimate of $21.08 million. On average, equities analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.